Investors /

Prospect Venture Partners

Prospect Venture Partners is a leading life sciences venture capital firm dedicated to building outstanding biomedical companies. With more than $1 billion of capital raised, the firm supports innovative companies from seed to growth stage, partnering with exceptional teams committed to excellence in the biomedical field.

Prospect Venture Partners

Prospect Venture Partners

Portfolio

Amicus Therapeutics

Amicus Therapeutics is a biotechnology company focused on developing advanced therapies to treat a range of human genetic diseases.

#Biotechnology

Amira Pharmaceuticals

Acquired by Bristol-Myers Squibb for $325 million.

#Pharmaceuticals

Aveo Oncology

Aveo Oncology is focused on developing targeted therapies for cancer.

#Oncology

Cabachon Aesthetics

Acquired by Merz Pharma Group for $600 million.

#Aesthetics

DFINE, Inc.

Acquired by Merit Medical Systems.

#Medical Devices

Gloucester Pharmaceuticals

Acquired by Celgene Corporation.

#Pharmaceuticals

Show More (25)

Key People

Russell Hirsch

Co-founder and Managing Director

David Schnell

Co-founder and Managing Director

Alex Barkas

Co-founder and Managing Director (In Memoriam)

LinkedIn